Genizon BioSciences
Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies
About Genizon BioSciences
Founded in 1999 and formerly known as Galileo Genomics, Genizon BioSciences was a Montreal-based genomics company that focused on discovering genes and biomarkers related to common diseases. The company's core strategy revolved around leveraging the unique genetic makeup of the Quebec founder population—a group descended from French immigrants who settled in the early 1600s—for its genome-wide association studies (GWAS). This particular population provided a relatively homogenous gene pool, which the company utilized to identify genetic susceptibilities for a range of complex disorders.
Genizon's business model was centered on forming partnerships with pharmaceutical companies to translate its genetic discoveries into new drug targets and diagnostic tools. The company successfully secured deals with major players like Pfizer, for Alzheimer's disease and attention-deficit disorder research, and Genentech, for Crohn's disease. Over its lifespan, Genizon raised a total of $130 million in funding over several rounds, with its final Series E round in 2008 bringing in $30.8 million. This capital was used to finance its extensive genome-wide association studies and to build comprehensive maps of genes and biomarkers for conditions such as schizophrenia, psoriasis, and metabolic syndrome.
Despite its initial promise and significant funding, Genizon BioSciences ceased operations and was placed into receivership in July 2011. The closure was primarily attributed to an inability to raise further funds as faster, more advanced technologies like next-generation sequencing surpassed Genizon's platform. The company's assets, including a substantial biobank of genetic material and advanced laboratory equipment, were subsequently handled by a court-appointed receiver.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Genizon BioSciences is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Genizon BioSciences in the Montreal ecosystem
The Genizon BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Biofund
MMV Financial- IDInvestissement Desjardins
Carnegie Asset Management
Series B and later5 investors entered at this stage
MVI- B(Biotech Turnaround Fund (BTF)
BioFund Management
Illumina- PVPfizer Ventures
Other known investors1 additional known investor
HealthCap
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genizon BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genizon BioSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









